Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma.

Cucè M, Gallo Cantafio ME, Siciliano MA, Riillo C, Caracciolo D, Scionti F, Staropoli N, Zuccalà V, Maltese L, Di Vito A, Grillone K, Barbieri V, Arbitrio M, Di Martino MT, Rossi M, Amodio N, Tagliaferri P, Tassone P, Botta C.

J Hematol Oncol. 2019 Mar 21;12(1):32. doi: 10.1186/s13045-019-0714-9.

2.

Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study.

Arbitrio M, Scionti F, Altomare E, Di Martino MT, Agapito G, Galeano T, Staropoli N, Iuliano E, Grillone F, Fabiani F, Caracciolo D, Cannataro M, Arpino G, Santini D, Tassone P, Tagliaferri P.

Clin Pharmacol Ther. 2019 Feb 10. doi: 10.1002/cpt.1391. [Epub ahead of print]

PMID:
30739312
3.

Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives.

Arbitrio M, Martino MTD, Scionti F, Barbieri V, Pensabene L, Tagliaferri P.

High Throughput. 2018 Dec 18;7(4). pii: E40. doi: 10.3390/ht7040040. Review.

4.

From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology.

Gallo Cantafio ME, Grillone K, Caracciolo D, Scionti F, Arbitrio M, Barbieri V, Pensabene L, Guzzi PH, Di Martino MT.

High Throughput. 2018 Oct 26;7(4). pii: E33. doi: 10.3390/ht7040033. Review.

5.

miR-22 suppresses DNA ligase III addiction in multiple myeloma.

Caracciolo D, Di Martino MT, Amodio N, Morelli E, Montesano M, Botta C, Scionti F, Talarico D, Altomare E, Gallo Cantafio ME, Zuccalà V, Maltese L, Todoerti K, Rossi M, Arbitrio M, Neri A, Tagliaferri P, Tassone P.

Leukemia. 2019 Feb;33(2):487-498. doi: 10.1038/s41375-018-0238-2. Epub 2018 Aug 17.

6.

Mouse models of multiple myeloma: technologic platforms and perspectives.

Rossi M, Botta C, Arbitrio M, Grembiale RD, Tagliaferri P, Tassone P.

Oncotarget. 2018 Apr 13;9(28):20119-20133. doi: 10.18632/oncotarget.24614. eCollection 2018 Apr 13. Review.

7.

The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis.

Ciliberto D, Staropoli N, Caglioti F, Chiellino S, Ierardi A, Ingargiola R, Botta C, Arbitrio M, Correale P, Tassone P, Tagliaferri P.

Crit Rev Oncol Hematol. 2018 May;125:69-77. doi: 10.1016/j.critrevonc.2018.03.003. Epub 2018 Mar 9. Review.

PMID:
29650279
8.

Genetic variants associated with Fabry disease progression despite enzyme replacement therapy.

Scionti F, Di Martino MT, Sestito S, Nicoletti A, Falvo F, Roppa K, Arbitrio M, Guzzi PH, Agapito G, Pisani A, Riccio E, Concolino D, Pensabene L.

Oncotarget. 2017 Nov 18;8(64):107558-107564. doi: 10.18632/oncotarget.22505. eCollection 2017 Dec 8.

9.

Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma.

Stamato MA, Juli G, Romeo E, Ronchetti D, Arbitrio M, Caracciolo D, Neri A, Tagliaferri P, Tassone P, Amodio N.

Oncotarget. 2017 Nov 20;8(63):106527-106537. doi: 10.18632/oncotarget.22507. eCollection 2017 Dec 5.

10.

Genetic variants associated with gastrointestinal symptoms in Fabry disease.

Di Martino MT, Scionti F, Sestito S, Nicoletti A, Arbitrio M, Hiram Guzzi P, Talarico V, Altomare F, Sanseviero MT, Agapito G, Pisani A, Riccio E, Borrelli O, Concolino D, Pensabene L.

Oncotarget. 2016 Dec 27;7(52):85895-85904. doi: 10.18632/oncotarget.13135.

11.

OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes.

Agapito G, Botta C, Guzzi PH, Arbitrio M, Di Martino MT, Tassone P, Tagliaferri P, Cannataro M.

Microarrays (Basel). 2016 Sep 23;5(4). pii: E24. doi: 10.3390/microarrays5040024.

12.

Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates.

Gallo Cantafio ME, Nielsen BS, Mignogna C, Arbitrio M, Botta C, Frandsen NM, Rolfo C, Tagliaferri P, Tassone P, Di Martino MT.

Mol Ther Nucleic Acids. 2016 Jun 21;5(6). doi: 10.1038/mtna.2016.36.

13.

DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.

Arbitrio M, Di Martino MT, Scionti F, Agapito G, Guzzi PH, Cannataro M, Tassone P, Tagliaferri P.

Oncotarget. 2016 Aug 16;7(33):54028-54050. doi: 10.18632/oncotarget.9927. Review.

14.

Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.

Arbitrio M, Di Martino MT, Barbieri V, Agapito G, Guzzi PH, Botta C, Iuliano E, Scionti F, Altomare E, Codispoti S, Conforti S, Cannataro M, Tassone P, Tagliaferri P.

Cancer Chemother Pharmacol. 2016 Jan;77(1):205-9. doi: 10.1007/s00280-015-2916-3. Epub 2015 Nov 25.

PMID:
26607259
15.

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.

Pitari MR, Rossi M, Amodio N, Botta C, Morelli E, Federico C, Gullà A, Caracciolo D, Di Martino MT, Arbitrio M, Giordano A, Tagliaferri P, Tassone P.

Oncotarget. 2015 Sep 29;6(29):27343-58. doi: 10.18632/oncotarget.4398.

16.

Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?

Cucinotto I, Fiorillo L, Gualtieri S, Arbitrio M, Ciliberto D, Staropoli N, Grimaldi A, Luce A, Tassone P, Caraglia M, Tagliaferri P.

J Drug Deliv. 2013;2013:905091. doi: 10.1155/2013/905091. Epub 2013 May 2.

17.

DMET-analyzer: automatic analysis of Affymetrix DMET data.

Guzzi PH, Agapito G, Di Martino MT, Arbitrio M, Tassone P, Tagliaferri P, Cannataro M.

BMC Bioinformatics. 2012 Oct 5;13:258. doi: 10.1186/1471-2105-13-258.

18.

Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.

Di Martino MT, Arbitrio M, Leone E, Guzzi PH, Rotundo MS, Ciliberto D, Tomaino V, Fabiani F, Talarico D, Sperlongano P, Doldo P, Cannataro M, Caraglia M, Tassone P, Tagliaferri P.

Cancer Biol Ther. 2011 Nov 1;12(9):780-7. doi: 10.4161/cbt.12.9.17781. Epub 2011 Nov 1.

PMID:
21892003
19.

A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling.

Di Martino MT, Arbitrio M, Guzzi PH, Leone E, Baudi F, Piro E, Prantera T, Cucinotto I, Calimeri T, Rossi M, Veltri P, Cannataro M, Tagliaferri P, Tassone P.

Br J Haematol. 2011 Aug;154(4):529-33. doi: 10.1111/j.1365-2141.2011.08622.x. Epub 2011 Apr 26. No abstract available.

20.

BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?

Tagliaferri P, Ventura M, Baudi F, Cucinotto I, Arbitrio M, Di Martino MT, Tassone P.

J Ovarian Res. 2009 Oct 13;2:14. doi: 10.1186/1757-2215-2-14.

Supplemental Content

Loading ...
Support Center